Targeting a Genetic Disease for Pediatric Patients
The FDA has approved a molecularly targeted therapeutic for treating certain patients with neurofibromatosis type 1 who have inoperable tumors.
Progress Against Cancer
The FDA has approved a molecularly targeted therapeutic for treating certain patients with neurofibromatosis type 1 who have inoperable tumors.
The FDA has approved a new combination of molecularly targeted therapeutics for treating metastatic colorectal cancer with a BRAF V600E gene mutation.
The FDA has approved a new combination of immunotherapy and chemotherapy as an initial treatment for extensive-stage small cell lung cancer.
The FDA approved using a combination of nivolumab and ipilimumab, two immune checkpoint inhibitors, to treat certain patients with hepatocellular carcinoma.
The FDA has approved a new therapeutic to treat adults with multiple myeloma whose cancer has progressed despite receiving at least two other treatments.
The FDA has expanded the use of the molecularly targeted therapeutic neratinib to include the treatment of certain patients with advanced or metastatic breast cancer
The FDA has approved a molecularly targeted therapy for epithelioid sarcoma, the first treatment approved for this rare form of soft tissue sarcoma.
The FDA has approved a molecularly targeted treatment for certain patients with gastrointestinal stromal tumors.
The FDA approved the use of the targeted therapeutic olaparib to treat certain pancreatic cancer patients whose disease has metastasized.
The FDA approved a new treatment for adults with advanced breast cancer that has developed resistance to other targeted therapies.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now